Prognostic factors and scoring systems in myelodysplastic syndromes

Haematologica

Volumn 83, Issue 4, 1998, Pages 358-368

  Sanz, Guillermo F ^a   Sanz, Miguel A ^a   Greenberg, Peter L ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Chromosomal abnormalities; Myelodysplastic syndromes; Prognosis; Prognostic factors

Indexed keywords

ACUTE LEUKEMIA; CYTOGENETICS; CYTOPENIA; DISEASE CLASSIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; TREATMENT PLANNING;

HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0031957591     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
2. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-23.
3. Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
4. Coiffier B, Adeleine P, Gentilhomme O, Felman P, Treille-Ritouet D, Bryon PA. Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients. Cancer 1987; 60:3029-32.
5. Aul C, Gatterman N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6:52-9.
6. Goasguen JE, Garand R, Bizet M, et al. Prognostic factors of myelodysplastic syndromes-A simplified 3-D scoring system. Leuk Res 1990; 14:255-60.
7. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59:425-33.
8. Tricot G, Vlietinck R, Boogaerts MA, et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985; 60:19-32.
9. Coiffier B, Adeleine P, Viala JJ, et al. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 1983; 52:83-90.
10. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
11. Kerkhofs H, Hermans J, Haak HL, Leeksma CHW. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65:73-81.
12. Mangi MH, Mufti GJ. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 1992; 79:198-205.
13. Sultan C, Sigaux F, Imbert M, et al. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 1981; 49:11-6.
14. Ríos A, Cañizo MC, Sanz MA, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75:26-33.
15. Maschek H, Gutzmer R, Choritz h, Georgii A. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies in 569 patients. Eur J Haematol 1994; 53:280-7.
16. Yunis JJ, Lobell M, Arnesen MA, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndromes and acute myelogenous leukaemia. Br J Haematol 1988; 68:189-94.
17. Billström R, Thiede T, Hansen S, et al. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur J Haematol 1988; 41:341-6.
18. Paquette RL, Landau EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82:590-9.
19. Greenberg PL. In vitro culture techniques defining biologic abnormalities in the myelodysplastic syndromes and myeloproliferative disorders. Clin Haematol 1986; 15:973-93.
20. Raymakers R, De Witte T, Loziasse J, et al. In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute non-lymphocytic leukaemia. Br J Haematol 1991; 78:35-41.
21. Oscier DG, Worsley A, Darlow S, Figes A, Williams JD, Hamblin TJ. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score. Leuk Res 1989; 13:833-9.
22. Tennant GB, Bowen DT, Jacobs A. Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia. Br J Haematol 1991; 77:296-300.
23. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990; 74:270-6.
24. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplatic syndromes. Am J Hematol 1993; 43:165-71.
25. Fenaux P, Morel P, Lai JL Cytogenetics in myelodysplastic syndromes. Semin Hematol 1996; 33:127-38.
26. Van Den Berghe H, Vermaelen K, Mecucci C, et al. The 5q- anomaly. Cancer Genet Cytogenet 1985; 17: 189-255.
27. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Cancer Genet Cytogenet 1988; 32:1-10.
28. Wattel E, Laī JL, Hebbar M, et al. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res 1993; 17:921-6.
29. Campbell LJ, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 1994; 8:67-72.
30. Fonatsch C, Haase D, Freund M, Bartels, Tesch H. Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 1991; 56:243-53.
31. Heim S, Mitelman F. Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 1986; 15:1003-21.
32. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7:499-508.
33. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76:1083-91.
34. Tricot G, Boogaerts MA, De Wolf-Peeters C, Van Den Berghe H, Verwilghen RL. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985; 59:659-70.
35. White AD, Culligan DJ, Hoy TG, Jacobs A. Extended cytogenetic follow-up of patients with myelodysplastic syndrome. Br J Haematol 1992; 81:499-502.
36. Ghaddar HM, Stass SA, Pierce S, et al. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7:1637-45.
37. Benitez J, Carbonell F, Sanchez-Fayos J, Heimpel H. Karyotypic evolution in patients with myelodysplastic syndromes. Cancer Genet Cytogenet 1985; 16:157-67.
38. Sanz GF, Sanz MA. Prognostic factors in myelodysplastic syndromes. Leuk Res 1992; 16:77-86.
39. Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996; 94: 116-9.
40. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anemia (AISA). Br J Haematol 1990; 74:45-52.
41. Foucar K, Langdon RM, Armitage JO, Olson DB, Caroll TJ. Myelodysplastic syndromes: a clinic and pathologic analysis of 109 cases. Cancer 1985; 56:553-61.
42. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67:1765-72.
43. Varela BL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes. Hematol Oncol 1985; 3:55-63.
44. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia 1996; 10:20-6.
45. Sanz GF, Sanz MA, Vallespí T, del Cañizo MC. Two types of acquired idiopathic sideroblastic anaemia. Br J Haematol 1990; 75:633-4.
46. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148-57.
47. Orazi A, Cattoretti G, Solino D, et al. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia 1993; 7:838-47.
48. Worsley A., Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988; 68:17-21.
49. Wattel E, Hecquet B, Grahek D, et al. Long term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. Leuk Res 1993; 17:733-9.
50. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF versus observation for myelodysplastic syndromes (MDS). Blood 1993; 82(suppl 1):196a.
51. Bernstein SH, Brunetto VL, Davey FR, et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J Clin Oncol 1996; 14:2486-94.
52. Pierre RV, Catovsky D, Mufti GJ, et al. Clinical cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 1989; 40:149-61.
53. Oscier D. Myelodysplastic syndromes. Bailliére's Clin Haematol 1987; 1:389-426.
54. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 1994; 87:746-54.
55. ISCN (1995). An International System for Human Cytogenetic Nomenclature. Mitelman F, ed. Basel: S. Karger, 1995.
56. Sokal G, Michaux JL, Van den Berghe H, et al. A new hematologic syndrome with a distinct karyotype: the 5q-chromosome. Blood 1975; 46:519-33.
57. United Kingdom Cancer Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosom Cancer 1992; 5:83-8.
58. Samuels BL, Larson RL, LeBeau MM, et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2:79-83.
59. Greenberg P, Cox C, Bennett J. International Prognostic Scoring System and other prognostic scoring systems for myelodysplastic syndromes. Blood 1997; 90:4233-4.
60. Second International Workshop on Chromosomes in Leukemia. Chromosomes in preleukemia. Cancer Genet Cytogenet 1980; 2:108.
61. Borgstrom GH. Cytogenetics in myelodysplastic syndromes. Scand J Haematol 1986; 45(suppl):74-7.
62. Suciu S, Kuse R, Weh, et al. Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990; 44:15-26.
63. Solé F, Prieto F, Badia L, et al. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 1992 ; 64:12-20.
64. Kaneko Y, Naseki N, Takasaki N, et al. Clinical and hematologic characteristics in acute leukemia with 11q23 translocations. Blood 1986; 67:484-91.
65. Berger R, Flandrin G, Bernheim A, et al. Cytogenetic studies in 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 1987; 29:9-21.
66. Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic working classification of the acute myeloid leukemias. Cancer Genet Cytogenet 1988; 30:1-15.
67. Greenberg P, Le Beau MM, Fenaux P, et al. Application of the International Prognostic Scoring System for MDS. Blood 1997; 90:2844-6.
68. Cortes J, Kantarjian H, O'Brien S, et al. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 1995; 9:115-7.
69. Cortes J, O'Brien S, Kantarjian H, et al. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 1994; 8:2174-8.
70. Taj A, Ross F, Vickers M, et al. t(8;21) myelodysplasia, an early presentation of M2 AML. Br J Haematol 1995; 89:890-2.
71. Oguma S, Yoshida Y, Uchino H, et al. Clinical characteristics on Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leuk Res 1995; 19:219-25.
72. Bader-Meunier B, Mielót F, Tchernia G, et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicenter study. Br J Haematol 1996; 92:344-50.
73. Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Seven F. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80:268-79.
74. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85:1742-50.
75. Del Cañizo MC, Sanz G, San Miguel JF, et al. Chronic myelomonocytic leukemia-clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur J Haematol 1989; 42:466-73.
76. Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukaemia: an analysis of 107 cases. J Clin Oncol 1988; 6:1417-24.
77. Catalano L, Improta S, de Laurentiis M, et al. Prognosis of chronic myelomonocytic leukemia. Haematologica 1996; 81:324-9.
78. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Castoldi G. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 1997; 82:25-30.
79. Hellström-Lindberg E, Robert K-H, Gahrton G, et al. A predictive model for the clinical response to low-dose Ara-C: a study of 102 patients with myelodysplastic syndrome or acute leukaemia. Br J Haematol 1992; 81:503-11.
80. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66:831-7.
81. Aul C, Schneider W. Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy? Haematol and Blood Transfusion: Acute Leukemias II 1990; 33:382-6.
82. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult denovo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77:497-501.
83. Michels S, Saumur J, Arthur D, Robinson L, Brunning R. Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients. Cancer 1989; 64:2340-6.
84. Seymour JF, Estey EH. The prognostic significance of Auer rods in myelodysplasia. Br J Haematol 1993; 85:67-76.
85. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90:2969-77.
86. Anderson JE, Appelbaum FR, Lloyd D, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82:677-81.
87. De Witte T, Gratwohl A. Bone marrow transplantation for myelodysplastic syndromes and secondary leukaemias. Br J Haematol 1993; 84:361-4.
88. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996; 88:358-65.
89. Anderson JE, Thomas DE. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS). Leuk Res 1997; 21 (suppl 1):51a.
90. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic bone marrow transplantation for myelodysplastic syndromes with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14:220-6.
91. Sepherd JD, Fung HC, Forrest DE, et al. Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndromes: evaluation of prognostic factors. Leuk Res 1997; 21 (suppl 1): 52a.
92. Sierra J, Carreras E, Rozman C, Champlin R, Rowlings P, Horowitz M. Bone marrow transplantation for myelodysplasia: the IBMTR data. Leuk Res 1997; 21 (suppl 1):51a.
93. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87:51-8.
94. Alessandrino EP, Astori C, Van Lint MT, et al. Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: outcome of 90 adult patients. Leuk Res 1997; 21 (suppl 1):52a.
95. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93:59-67
96. Balduini CL, Guarnone R, Pecci A, Centenara E, Ascari E. International Prognostic Scoring System and other prognostic systems for myelodysplastic syndromes. Blood 1997; 90:4232-3.